wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q36517533-48D60D3E-1C3D-48C4-8122-BD9623F339C3
Q36517533-48D60D3E-1C3D-48C4-8122-BD9623F339C3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36517533-48D60D3E-1C3D-48C4-8122-BD9623F339C3
Research needs in allergy: an EAACI position paper, in collaboration with EFA.
P2860
Q36517533-48D60D3E-1C3D-48C4-8122-BD9623F339C3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36517533-48D60D3E-1C3D-48C4-8122-BD9623F339C3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d994fb9de8b0bb83abdc1f7b4e89bf9cc0950b98
P2860
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.